Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 19

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 19
---
, and Series C-3 Warrant is exercisable for one share of common stock, will have an exercise price of $                per share, and will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided, however, that if the Pricing Conditions are met, the Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The Series C-1 Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series C-2 Warrants will expire on the twenty-four-month anniversary of the Initial Exercise Date. The Series C-3 Warrants will expire on the nine-month anniversary of the Initial Exercise Date.Description of pre-funded warrantsIf the issuance of shares of our common stock to a purchaser in this offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering or if such purchaser otherwise elects to purchase pre-funded warrants, then such purchaser may purchase, if they so choose, in lieu of the shares of our common stock that would result in such excess ownership, a pre-funded warrant to purchase shares of our common stock for a purchase price per share of common stock subject to such pre-funded warrant equal to the per share public offering price for the common stock to be sold in this offering less $0.0001. Each pre-funded warrant will have an exercise price of $0.0001 per share, will be exercisable upon issuance and may be exercised at any time until all of the pre-funded warrants are exercised in full. Purchasers of pre-funded warrants will also receive accompanying warrants as if such purchasers were buying shares of our common stock in this offering. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of these pre-funded warrants.Common stock outstanding before offering:64,768,830 sharesCommon stock outstanding after this offeringshares of common stock, assuming full exercise of the pre-funded warrants issued in this offering and no exercise of the Warrants being issued in this offering.Use of proceeds:We currently intend to use the net proceeds from this offering for working capital and general corporate purposes. See “Use of Proceeds” on page 59 of this prospectus.​​​Risk factorsAn investment in our securities involves a high degree of risk and could result in a loss of your entire investment. Prior to making an investment decision,